Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||ERBB2 V697L|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 V697L||Advanced Solid Tumor||predicted - sensitive||Neratinib||Case Reports/Case Series||Actionable||In a Phase II trial, a patient with cancer of unknown primary involving the head and neck that harbored ERBB2 (HER2) V697L demonstrated a response to treatment with Nerlynx (neratinib) that lasted 13 months (PMID: 29247016).||29247016|
|ERBB2 V697L||triple-receptor negative breast cancer||sensitive||Neratinib||Phase II||Actionable||In a Phase II trial, a triple-negative breast cancer patient harboring ERBB2 V697L demonstrated a response to treatment with Nerlynx (neratinib) (PMID: 29247016).||29247016|
|ERBB2 V697L||endometrial cancer||predicted - resistant||Neratinib||Case Reports/Case Series||Actionable||In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) V697L (PMID: 29420467; NCT01953926).||29420467|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02673398||Phase II||Neratinib||Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer||Active, not recruiting|
|NCT04172597||Phase II||Poziotinib||A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies||Recruiting|